Search: WFRF:(Slack Robert J.) >
Target inhibition o...
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis
-
- Hirani, Nikhil (author)
- University of Edinburgh
-
- MacKinnon, Alison C. (author)
- Galecto Biotech ApS, Denmark,University of Edinburgh
-
- Nicol, Lisa (author)
- University of Edinburgh
-
show more...
-
- Ford, Paul (author)
- Galecto Biotech ApS, Denmark
-
- Schambye, Hans (author)
- Galecto Biotech ApS, Denmark
-
- Pedersen, Anders (author)
- Galecto Biotech ApS, Denmark
-
- Nilsson, Ulf J. (author)
- Lund University,Lunds universitet,Centrum för analys och syntes,Kemiska institutionen,Institutioner vid LTH,Lunds Tekniska Högskola,Centre for Analysis and Synthesis,Department of Chemistry,Departments at LTH,Faculty of Engineering, LTH
-
- Leffler, Hakon (author)
- Lund University,Lunds universitet,Avdelningen för mikrobiologi, immunologi och glykobiologi - MIG,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Microbiology, Immunology and Glycobiology - MIG,Department of Laboratory Medicine,Faculty of Medicine
-
- Sethi, Tariq (author)
- Galecto Biotech ApS, Denmark
-
- Tantawi, Susan (author)
- Galecto Biotech ApS, Denmark
-
- Gravelle, Lise (author)
- Galecto Biotech ApS, Denmark
-
- Slack, Robert J. (author)
- Galecto Biotech ApS, Denmark
-
- Mills, Ross (author)
- University of Edinburgh
-
- Karmakar, Utsa (author)
- University of Edinburgh
-
- Humphries, Duncan (author)
- University of Edinburgh
-
- Zetterberg, Fredrik (author)
- Galecto Biotech ApS, Denmark
-
- Keeling, Lucy (author)
- Exploristics Ltd
-
- Paul, Lyn (author)
- Royal Brompton and Harefield NHS Foundation Trust,Imperial College London
-
- Molyneaux, Philip L. (author)
- Imperial College London,Royal Brompton and Harefield NHS Foundation Trust
-
- Li, Feng (author)
- University of Edinburgh
-
- Funston, Wendy (author)
- University of Newcastle upon Tyne
-
- Forrest, Ian A. (author)
- Royal Victoria Infirmary
-
- Simpson, A. John (author)
- Royal Victoria Infirmary,University of Newcastle upon Tyne
-
- Gibbons, Michael A. (author)
- University of Exeter
-
- Maher, Toby M. (author)
- Royal Brompton and Harefield NHS Foundation Trust,University of Southern California,Imperial College London
-
show less...
-
(creator_code:org_t)
- 2020-11-19
- 2021
- English.
-
In: European Respiratory Journal. - : European Respiratory Society (ERS). - 0903-1936 .- 1399-3003. ; 57:5
- Related links:
-
http://dx.doi.org/10... (free)
-
show more...
-
https://erj.ersjourn...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Galectin (Gal)-3 is a profibrotic β-galactoside-binding lectin that plays a key role in the pathogenesis of idiopathic pulmonary fibrosis (IPF) and IPF exacerbations. TD139 is a novel and potent small-molecule inhibitor of Gal-3. A randomised, double-blind, multicentre, placebo-controlled, phase 1/2a study was conducted to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled TD139 in 36 healthy subjects and 24 patients with IPF. Six dose cohorts of six healthy subjects were evaluated (4:2 TD139:placebo ratio) with single doses of TD139 (0.15–50 mg) and three dose cohorts of eight patients with IPF (5:3 TD139: placebo ratio) with once-daily doses of TD139 (0.3–10 mg) for 14 days. Inhaled TD139 was well tolerated with no significant treatment-related side-effects. TD139 was rapidly absorbed, with mean time taken to reach maximum plasma concentration (Cmax) values ranging from 0.6 to 3 h and a plasma half-life (T1/2) of 8 h. The concentration of TD139 in the lung was >567-fold higher than in the blood, with systemic exposure predicting exposure in the target compartment. Gal-3 expression on alveolar macrophages was reduced in the 3 and 10 mg dose groups compared with placebo, with a concentration-dependent inhibition demonstrated. Inhibition of Gal-3 expression in the lung was associated with reductions in plasma biomarkers centrally relevant to IPF pathobiology (platelet-derived growth factor-BB, plasminogen activator inhibitor-1, Gal-3, CCL18 and YKL-40). TD139 is safe and well tolerated in healthy subjects and IPF patients. It was shown to suppress Gal-3 expression on bronchoalveolar lavage macrophages and, in a concerted fashion, decrease plasma biomarkers associated with IPF progression.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database
- By the author/editor
-
Hirani, Nikhil
-
MacKinnon, Aliso ...
-
Nicol, Lisa
-
Ford, Paul
-
Schambye, Hans
-
Pedersen, Anders
-
show more...
-
Nilsson, Ulf J.
-
Leffler, Hakon
-
Sethi, Tariq
-
Tantawi, Susan
-
Gravelle, Lise
-
Slack, Robert J.
-
Mills, Ross
-
Karmakar, Utsa
-
Humphries, Dunca ...
-
Zetterberg, Fred ...
-
Keeling, Lucy
-
Paul, Lyn
-
Molyneaux, Phili ...
-
Li, Feng
-
Funston, Wendy
-
Forrest, Ian A.
-
Simpson, A. John
-
Gibbons, Michael ...
-
Maher, Toby M.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Respiratory Medi ...
- Articles in the publication
-
European Respira ...
- By the university
-
Lund University